Cargando…

Targeted Deep Sequencing Reveals Unrecognized KIT Mutation Coexistent with NF1 Deficiency in GISTs

PURPOSE: NF1-deficient GISTs account for about 1% of gastrointestinal stromal tumors (GISTs) and are usually considered as a subtype of KIT/PDGFRA wild-type GISTs that have no detectable KIT and PDGFRA mutations. Some KIT/PDGFRA wild-type GISTs actually have cryptic KIT mutations (mKIT). So we inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jinchun, Zhou, Haiyan, Yi, Xiaoping, He, Qiongzhi, Lei, Tianxiang, Tan, Fengbo, Liu, Heli, Li, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811451/ https://www.ncbi.nlm.nih.gov/pubmed/33469372 http://dx.doi.org/10.2147/CMAR.S280174

Ejemplares similares

KIT mutation in a naïve succinate dehydrogenase‐deficient gastric GIST
por: Brcic, Iva, et al.
Publicado: (2019)

CT-based assessment of sarcopenia for differentiating wild-type from mutant-type gastrointestinal stromal tumor
por: Yi, Xiaoping, et al.
Publicado: (2023)

Secondary KIT mutations: the GIST of drug resistance and sensitivity
por: Napolitano, Andrea, et al.
Publicado: (2019)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
por: Belinsky, Martin G., et al.
Publicado: (2017)

Prognosis and predictive value of KIT exon 11 deletion in GISTs
por: Bachet, J-B, et al.
Publicado: (2009)

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014)

Endoscopic or Surgical Resection for Patients with 2–5cm Gastric Gastrointestinal Stromal Tumors: A Single-Center 12-Year Experience from China
por: Lei, Tianxiang, et al.
Publicado: (2020)

Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways
por: Pantaleo, Maria A, et al.
Publicado: (2015)

KIT Mutation and Loss of 14q May Be Sufficient for the Development of Clinically Symptomatic Very Low-Risk GIST
por: Klinke, Olaf Karl, et al.
Publicado: (2015)

SDHA Germline Mutations in SDH-Deficient GISTs: A Current Update
por: Schipani, Angela, et al.
Publicado: (2023)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Targeted therapy in SDH-deficient GIST
por: Nannini, Margherita, et al.
Publicado: (2021)

Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: A case report
por: Efstathios, Papalambros, et al.
Publicado: (2007)

The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor
por: Liu, Peng, et al.
Publicado: (2020)

ETV1 is a lineage-specific survival factor in GIST and cooperates with KIT in oncogenesis
por: Chi, Ping, et al.
Publicado: (2010)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Coexistence of two accessory flexor pollicis longus heads or coexistence of two-headed flexor pollicis longus with an unrecognized anatomical structure?
por: Zielinska, Nicol, et al.
Publicado: (2021)

Gastrointestinal Stromal Tumours (GISTs) with KRAS Mutation: A Rare but Important Subset of GISTs
por: Mullen, Dorinda, et al.
Publicado: (2023)

Preferential MGMT methylation could predispose a subset of KIT/PDGFRA-WT GISTs, including SDH-deficient ones, to respond to alkylating agents
por: Ricci, Riccardo, et al.
Publicado: (2019)

Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism
por: Théou-Anton, N, et al.
Publicado: (2006)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

A GIST or not a GIST? That is the question
por: Chrysanthos, Nikolaos, et al.
Publicado: (2014)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib
por: Lei, Tianxiang, et al.
Publicado: (2021)

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients
por: Moura, David S., et al.
Publicado: (2018)

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019)

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Synchronous double gastric tumors: GIST or not GIST
por: Sayida, Sa’d, et al.
Publicado: (2020)

Coexistence of gastric cancer and gastric GIST with intra-tumor bleeding: successful embolization with subsequent total gastrectomy
por: Nishiyama, Raisuke, et al.
Publicado: (2021)

Establishment and Verification of Synchronous Metastatic Nomogram for Gastrointestinal Stromal Tumors (GISTs): A Population-Based Analysis
por: Li, Yuqiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_23igt60ap8ajid7uig9qethtbu